Hepatocellular carcinoma (HCC) associated with chronic liver disease evolves from precancerous lesions and early HCC to a progressed form. Nodule-in-nodule-type HCC (progressed HCC within early HCC) represents the transition from early to progressed HCC and, therefore, is useful in molecular genetic analysis of HCC progression during multistage carcinogenesis. We compared expression profiles among 7 early components and 7 progressed components of nodule-in-nodule-type HCCs and their corresponding noncancerous liver tissues with oligonucleotide array. Of the approximately 12,600 genes that were analyzed, a set of 95 genes provided a molecular signature that distinguished between early HCC components and their noncancerous liver tissues, and a set of 92 genes distinguished between progressed and early HCC components. Of these genes, the most abundantly up-regulated gene in early HCC components (P < .001) was heat-shock protein 70 (HSP70). Real-time quantitative reverse transcription polymerase chain reaction (RT-PCR) confirmed this finding. Further immunohistochemical examination of HSP70 revealed its significant overexpression in early HCC compared with precancerous lesions (P < .001) and in progressed HCC compared with early HCC (P < .001). In conclusion, molecular signatures were clearly different in noncancerous liver tissue as compared with the early and progressed components of nodule-in-nodule-type HCC. Moreover, HSP70 could be a sensitive marker for the differential diagnosis of early HCC from precancerous lesion or noncancerous liver, a difficult distinction for pathologists due to very well differentiated histology with little atypia in early HCC. (HEPATOLOGY 2003;37:198-207.) H epatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide and one of the leading causes of cancer death in Japan. 1 Despite remarkable advances in diagnostic and therapeutic techniques, the incidence of HCC is still on the increase. HCC occurs mainly in livers that are chronically diseased as a result of hepatitis virus infection. 2 Progression often leads to vascular invasion and intrahepatic metastasis. As is known for other cancers, 3 HCC is also characterized by an obvious multistage process of tumor progression. Histopathologic and molecular biological studies have revealed the multistep development of human HCCs. [4] [5] [6] [7] It has been shown that small nodular hypercellular lesions known as adenomatous hyperplasia (AH) or atypical AH (AAH: AH with focally increased atypia but too indefinite for a diagnosis of HCC) appear in damaged liver infected with hepatitis virus B or C. These lesions develop into early HCC, which corresponds to in situ or microinvasive carcinoma, in which the portal tracts within the nodule are preserved, and then into progressed HCC through the stage of nodule-in-nodule-type HCC (progressed HCC within early HCC), which indicates a transition from early to progressed HCC. These pathologic findings are also supported by radiologic findings. 8,9
H epatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide and one of the leading causes of cancer death in Japan. 1 Despite remarkable advances in diagnostic and therapeutic techniques, the incidence of HCC is still on the increase. HCC occurs mainly in livers that are chronically diseased as a result of hepatitis virus infection. 2 Progression often leads to vascular invasion and intrahepatic metastasis. As is known for other cancers, 3 HCC is also characterized by an obvious multistage process of tumor progression. Histopathologic and molecular biological studies have revealed the multistep development of human HCCs. [4] [5] [6] [7] It has been shown that small nodular hypercellular lesions known as adenomatous hyperplasia (AH) or atypical AH (AAH: AH with focally increased atypia but too indefinite for a diagnosis of HCC) appear in damaged liver infected with hepatitis virus B or C. These lesions develop into early HCC, which corresponds to in situ or microinvasive carcinoma, in which the portal tracts within the nodule are preserved, and then into progressed HCC through the stage of nodule-in-nodule-type HCC (progressed HCC within early HCC), which indicates a transition from early to progressed HCC. These pathologic findings are also supported by radiologic findings. 8, 9 On the basis of this current knowledge of multistage hepatocarcinogenesis, high-risk patients are closely followed up, and increasing numbers of small equivocal lesions are detected by imaging diagnosis. Ultrasoundguided needle biopsy is performed on such lesions, and if they are diagnosed histologically as cancer they are treated. However, as is the case with other early cancers, such as those of the lung, 10 stomach, 11 and colon, 12 early HCC shows minimum atypia, and lacks definite invasive or destructive growth. 6 Therefore, it is often difficult, even for the hepatopathologist, to distinguish regenerative nodules, precancerous lesions, and early HCC. For these reasons, the discovery of an objective molecular marker that will help to standardize histologic diagnosis of early HCC and lead to appropriate treatment is eagerly anticipated.
In addition to this diagnostic problem, the molecular mechanisms of hepatocarcinogenesis are far from clear. A molecular understanding of multistep hepatocarcinogenesis is an important step toward the identification of additional biomarkers and new therapeutic targets with increased specificity for HCC development. The establishment of microarray methods for large-scale analysis of gene expression 13, 14 has made it possible to seek molecular markers for cancer classification and outcome prediction and to identify molecules involved in carcinogenesis in a variety of tumor types. [15] [16] [17] We compared expression profiles among 7 early components and 7 progressed components of nodule-in-nodule-type HCCs and their corresponding noncancerous liver tissues with oligonucleotide array to identify genes generally involved in multistep hepatocarcinogenesis. We showed that molecular signatures distinguished between early HCC components and their noncancerous liver tissues and between progressed and early HCC components. We also found that heat-shock protein 70 (HSP70) is involved in multistep hepatocarcinogenesis and could be a sensitive marker for the differential diagnosis of early HCC from precancerous lesions or from noncancerous liver tissues.
Materials and Methods
Tissue Samples. Seven pairs of nodule-in-noduletype HCCs and corresponding noncancerous liver tissues were obtained from patients who underwent surgical resection at the National Cancer Center Hospital, Japan. For each nodule-in-nodule-type HCC, the early components, in which the underlying liver structure within the nodule was well preserved, and the progressed components, which showed definite destructive or expansive growth ( Fig. 1) , were separated macroscopically. This classification was confirmed histologically by 2 pathologists. Specimens were immediately cut into small pieces, snap-frozen in liquid nitrogen, and stored until use. Histologically, early components were all well differentiated HCCs and progressed components were 2 well, and 5 moderately differentiated HCCs. Serologically, 1 case was positive for hepatitis-B-surface-antigen, 5 cases were hepatitis C virus (HCV)-positive, and 1 was negative for both. For immunohistochemical analysis, 18 RNA Preparation and Oligonucleotide Array. Total RNA was extracted from the bulk tissues with Trizol reagent (Invitrogen Corp., Carlsbad, CA). Biotin-labeled complementary RNA was synthesized from 10 g of total RNA derived from each sample using a Super Script Choice System (Gibco-BRL, Rockville, MD) and BioArray High Yield RNA Transcript Labeling Kit (Enzo Diagnostics, Farmingdale, NY) accord- ing to the manufacturers' instructions. Hybridization of each complementary RNA to the probe array, HGU95Av2 (Affymetrix, Santa Clara, CA), and detection of the signals were performed as instructed by the manufacturer.
Data Analysis. Using the Microarray Suite 4.0 software package (Affymetrix), the hybridization intensity data were normalized to 1,000 of total signal intensities of each array and transformed for each probe set into average difference representing the mean difference of signal intensity between the match and mismatch probe pairs and, thus, the expression level of the target gene. Two-way hierarchical clustering algorithm 19 of the genes and individual samples was performed by the software, GeneSpring (Silicon Genetics, Redwood City, CA), to arrive at a Pearson correlation coefficient . 19 Real-time quantitative RT-PCR analysis was performed as reported previously. 20 The primer set 5Ј-AGGCCGA-CAAGAAGAAGGTGCT-3Ј (forward) and 5Ј-TGGTA-CAGTCCGCTGATGATGG-3Ј (reverse) was designed against the 3Ј untranslated region of HSP70. For standardization of the amount of RNA, expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in each sample was quantified by using the primer set 5Ј-GAAGGTGAAG-GTCGGAGTC-3Ј (forward) and 5Ј-CCCGAATCACAT-TCTCCAAGAA-3Ј (reverse). All PCR reactions were performed with the SYBR Green PCR Core Reagents kit (Perkin-Elmer Applied Biosystems, Foster City, CA) under the following conditions: 1 cycle at 50°C for 2 minutes, 1 cycle at 95°C for 10 minutes, then 40 cycles at 95°C for 15 seconds and 60°C for 1 minute. Real-time detection of the emission intensity of SYBR Green was performed with an ABI prism 7700 Sequence Detector (Perkin-Elmer Applied Biosystems), as reported previously. 21 Quantitative RT-PCR was performed at least 3 times, including a no-template control as a negative control. Statistical analyses were performed by the paired t test.
Immunohistochemistry. Immunohistochemical staining was performed on formalin-fixed, paraffin-embedded tissue sections by an immunoperoxidase method, as described previously. 22 Briefly, each section was deparaffinized, rehydrated, and incubated with fresh 0.3% hydrogen peroxide in methanol for 30 minutes at room temperature and then washed in phosphate-buffered saline. Normal swine serum (DAKO, Glostrup, Denmark) was applied for 30 minutes and removed. The sections were incubated with mouse monoclonal antibodies for HSP70 (SC-24; Santa Cruz Biotechnology, Santa Cruz, CA) at a dilution of 1:500 overnight at 4°C, washed 3 times in phosphate-buffered saline, and incubated with secondary antibody for 30 minutes at room temperature. For detection, a Vectastatin Elite ABC kit (Vector Laboratories, Burlingame, CA) was used.
Staining Evaluation. Staining was evaluated by 2 independent observers. Equal or more intense nuclear and cytoplasmic staining compared with bile duct was considered positive. The positivity index was expressed as the percentage of positive cells in each lesion. Statistical analyses were performed by the unpaired t test.
Results

Two-Way Hierarchical Clustering Algorithm.
To identify genes generally involved in multistep hepatocarcinogenesis, we compared expression profiles between 7 early HCC components and their noncancerous liver counterparts and between 7 progressed and 7 early HCC components by using oligonucleotide array. We filtered all genes, with the following limits: 1. presence (i.e., exactly expressed in the sample); 2. average difference of more than 1,000 in at least 7 of 14 samples in each of the 2 groups; 3. Mann-Whitney U test with significance set at P Ͻ .05 to identify genes expressed differently between the 2 groups. In the 95 and 92 genes selected under the above criteria, a 2-way hierarchical clustering algorithm successfully distinguished between early components and their noncancerous liver tissues ( Fig. 2A) , and between progressed components and early components (Fig. 2B) .
Next, we listed genes that met an additional limit: 4. a more than 2-fold increase of average difference between 2 groups, to identify genes with more significant difference of expression in noncancerous liver tissues, early components, or progressed components (Tables 1 and 2 ). Six genes were up-regulated and 18 genes were down-regulated in early components compared with in noncancerous liver tissues (Table 1) . Thirteen genes were upregulated and 15 were down-regulated in progressed components compared with in early components ( Table 2) .
HSP70 mRNA Expression in HCC. Of the genes listed in Table 1 , the most abundantly up-regulated gene in early components (Mann-Whitney U test, P Ͻ .001) was HSP70. To confirm our findings, we next analyzed the level of HSP70 messenger RNA (mRNA) by real-time quantitative RT-PCR. In 5 of 7 cases, the expression level in the early component was up-regulated compared with that in the corresponding noncancerous liver tissue, and in 3 of 7 cases, the expression level in the progressed component was up-regulated compared with that in the corresponding early component (Fig. 3A) . The average level of expression of HSP70 mRNA in each component of nodule-in-nodule-type HCC was up-regulated in a stepwise manner: noncancerous liver (0.16 Ϯ 0.09) versus early component (0.30 Ϯ 0.18), P ϭ .018; early component versus progressed component (0.48 Ϯ 0.29), P ϭ .056 (Fig. 3B) .
Protein Expression of HSP70. To determine whether HSP70 is also overexpressed at the protein level and increasingly expressed according to the stepwise progression of hepatocarcinogenesis, we employed an antibody against HSP70 in an immunohistochemical study (Fig. 4) and counted the percentage of positive cells in each lesion (Fig. 5) . Hepatocytes in noncancerous liver tissue with chronic hepatitis or cirrhosis showed no immunostaining or only focal and faint staining in the nucleus. However, the bile duct epithelium always stained strongly and thus served as an internal control of positive staining ( Fig. 4B and D) . Some sinusoidal cells also showed moderate staining. All cases of AH were negative for HSP70 (Fig. 4B) , with the exception of 1 case that showed 5% positive staining. Sixty percent positivity was observed in one case of AAH, and 20% in another. In contrast, we detected immunoreactivity ranging up to 80% in most cases of early HCC (Fig. 4D) and in early components of nodule-in-nodule-type HCC (Fig. 4F) . The progressed components and progressed HCCs showed more widespread staining than the early components (Fig. 4F) . In progressed HCC, no specific correlation was found between immunostaining for HSP70 and clinicopathologic features such as differentiation or presence of vascular invasion (data not shown). As shown in Fig. 4 , strong immunoreactivity was observed in both the nucleus and cytoplasm, and, in most cases, the intensity of staining of the cytoplasm corresponded to that of the nucleus. The percentage of positive cells increased gradually according to the stepwise progression of hepatocarcinogenesis, and was significantly different between the precancerous lesions AH ϩ AAH (3.49 Ϯ 10.9) and early HCC (32.9 Ϯ 24.3) (P Ͻ .001), and between early HCC and progressed HCC (60.8 Ϯ 24.6) (P Ͻ .001).
Discussion
The recent development of complementary DNA microarray or oligonucleotide array technology, a highthroughput method of monitoring gene expression, has made it possible to analyze the expression of thousands of genes at once. 13, 14 Consequently, new classifications of cancers now can be proposed on the basis of the altered expression of multiple genes in tumor tissues. [15] [16] [17] 23 For example, molecularly distinct subtypes, with significant differences in clinical behavior, have been recognized on the basis of differences in gene expression patterns for morphologically indistinguishable diffuse large B cell lymphoma. 15 To elucidate the characteristic changes associated with multistep hepatocarcinogenesis, we globally analyzed the gene expression of 7 early components and 7 progressed components of nodule-in-nodule-type HCC representing a transition from early to progressed HCC and their corresponding noncancerous liver tissues. We showed that a 2-way hierarchical clustering algorithm successfully distinguished between noncancerous liver tissues, early components, and progressed components. These results indicate that there is a clear difference in molecular signatures between each step in the progression of HCC. Our present approach was able to show genes involved in early hepatocarcinogenesis commonly seen in HCV-related cases. Another approach for revealing differences between hepatitis B virus (HBV)-and HCV-related hepatocarcinogenesis is expected. We further showed that HSP70 could be a sensitive marker for the differential diagnosis of early HCC from precancerous lesions or noncancerous liver tissue, a diagnosis that is difficult even for pathologists because of the very well differentiated histology with minimum atypia seen in early HCC. Although early HCC is defined on the basis of histopathologic [4] [5] [6] [7] and clinical studies, 8, 9 the molecular changes that occur in early HCC are not well understood. Early HCC is characterized by an increase of cell density and growth, 6 but no positive molecular marker has yet been identified. The situation is the same in other types of early cancer, and this is the first example that shows that gene expression profiling is a promising method for finding molecular markers useful for the diagnosis of early cancer. We expect that similar efforts would facilitate standardization of histologic diagnosis of early cancer in many organs. It is not clear why HSP70 expression increases in early HCC and progressed HCC. HSP70 is a physiologically essential, highly conserved protein in both prokaryotes and eukaryotes that performs a variety of vital intracellular chaperoning functions. 24 Overexpression of HSP70 has been reported in various human tumors. [25] [26] [27] [28] [29] Overexpression of HSP70 also has been observed in cultured cells transformed with c-myc 30 or H-ras, 31 or cotransformed with H-ras/p53, 32 suggesting involvement of HSP70 in transformation or progression. Although many reports have described HSP70 expression in hepatoma cell lines, 33 to our knowledge, there have been no descriptions of HSP70 overexpression in human HCC tissues except for recent reports by Iizuka, 34 who listed examples of HSP70 upregulation in human HCC tissues in microarray studies, and by Yin, 35 who described overexpression of HSP70 in HCC. Overexpression of HSP70 in HCC is comparatively novel, and this is the first report of HSP70 overexpression in early hepatocarcinogenesis. It is possible that HSP70 expression increases as a result of tumorigenesis. For example, a stressful environment in early HCC (nutrient depletion and hypoxia resulting from insufficient blood supply 8, 9 ) may stimulate HSP synthesis.
In addition to HSP70, we were able to identify several candidate genes involved in multistep hepatocarcinogenesis. Genes classified in the category of immune system detoxification were down-regulated in cancer cells. 36 Some of the up-regulated genes previously had been correlated with cellular dysplasia and tumor malignancy in several types of cancers. For example, type I sigma receptor 37 and nma, 38 which are transmembrane proteins, are known to be expressed in a variety of human tumor cells. Lipocalin 2, neutrophil-gelatinase-associated lipocalin, is reported to be overexpressed in some carcinomas. 39 Granulin, the glioma-associated growth factor gene, is reported to be overexpressed in brain tumors. 40 Overexpression of the midkine gene 41 and collagen type IV 42 have been described in HCC. The function of adenylylcyclase-associated protein 2 is unknown, but its homologue CAP forms a complex with adenylyl cyclase in yeast. 43 CAP overexpressed in early HCC component was confirmed by real-time quantitative RT-PCR (unpublished observation) and might be involved in hepatocarcinogenesis. Further analysis of these genes in multistage hepatocarcinogenesis is important.
In conclusion, the molecular signatures were clearly different between noncancerous liver tissue and the early and progressed components of nodule-in-nodule-type HCC. It was indicated also that HSP70 could be a sensitive marker for the differential diagnosis of early HCC from precancerous lesions such as AH and AAH or noncancerous liver tissue. 
